Leman Biotech
China - Shenzhen
BiotechnologyFocus: AI-enabled metabolic cancer immunotherapy
Leman Biotech is a life sciences company focused on AI-enabled metabolic cancer immunotherapy.
OncologyMetabolic Diseases
Funding Stage
PUBLIC
Open Jobs
1
Pipeline & Clinical Trials
Metabolically Armed CD19 CAR-T cells
Diffuse Large B-cell LymphomaClinical Trials (1)
NCT06120166Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research
Phase 1Metabolically Armed CD19 CAR-T cells
Non-hodgkin Lymphoma,B CellClinical Trials (1)
NCT06716164Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research
Phase 1Metabolically Armed BCMA CAR-T cells.
Multiple Myeloma (MM)Clinical Trials (1)
NCT07085559Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
Phase 1Metabolically Armed TIL cells
Advanced Solid TumorsClinical Trials (1)
NCT07106814Safety and Efficacy of Metabolically Armed Tumor-lnfiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors
Phase 1Metabolically Armed CD19 CAR-T cells
Systemic Lupus ErythematosusClinical Trials (1)
NCT06711146Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research
Phase 1Metabolically Armed CD19 CAR-T cells
Acute Lymphoblastic LeukemiaClinical Trials (1)
NCT06277011Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
Phase 1Metabolically Armed TIL cells.
Advanced Solid TumorsClinical Trials (1)
NCT07349160Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors
Phase 1Metabolically Armed CD19 CAR-T cells
B-cell Acute Lymphoblastic LeukemiaClinical Trials (1)
NCT05747157Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research
Phase 1Metabolically Armed CD19 CAR-T cells
Acute Lymphoblastic LeukemiaClinical Trials (1)
NCT06393335Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
Phase 1Metabolically Armed EGFRvIII CAR-T cells
Glioblastoma (GBM)Clinical Trials (1)
NCT07244666Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma
Phase 1Metabolically Armed CD19 CAR-T cells
Diffuse Large B-cell LymphomaClinical Trials (1)
NCT05715606Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research
Phase 1Open Jobs (1)
Interview Prep Quick Facts
Founded: 2023
Portfolio: 11 clinical trials
Open Roles: 1 active job